SPOTLIGHT: Hana expects delay

Manufacturing problems are delaying development of Hana Bioscience's Zensana, an oral spray for treating nausea prompted by chemotherapy, radiation and cancer surgery. "Precipitated" material was found in batches of the drug, which may force Hana to change the way it is formulated. The snafu will lead to a delay in the FDA's approval of Zensana, said CEO Mark Ahn, who added that Hana is still completely committed to the therapy. Release | Report

Suggested Articles

Bausch Health is paying $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, with a promise of $40 million to come.

Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D.

The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line AML drug licensed from Bischofberger's former employer.